Found More Study Details on the Novartis Site

Finally found something on the Internet regarding this study. It is from the Drug company's Novartis website.
Here is the text:
Thanks,
Greg

RADIANT-1: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) after chemotherapy failure Study CRAD001C2239
Novartis Oncology is conducting a clinical research study to find out if an investigational drug is safe and effective in people who have advanced pancreatic neuroendocrine (cells producing hormones) cancer. This cancer is also known as islet cell carcinoma. Patients must have previously received an adequate course of chemotherapy (i.e. at least 3 consecutive cycles or months of treatment with the same drug or regimen). Patients should also have documented objective progression of disease by RECIST criteria while receiving cytotoxic chemotherapy or documented progression at any time after receiving an adequate course of chemotherapy. The purpose of this clinical research study is to learn if the investigational drug can shrink or slow the growth of advanced pancreatic neuroendocrine tumors. The physical state of participants, changes in the size of their tumors and laboratory findings will be taken to help determine the safety and effectiveness of the investigational drug. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). Trial phase: Phase 2Participation Duration: Participants will visit the study clinic and draw blood every 2 weeks during the first month; then once a month until study completion. Radiological scans (CT and/or MRI imaging) are expected every 3 months. Study will last approx 16 months.Protocol Number: CRAD001C2239